Efficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open-label Trial

Purpose: To assess the efficacy and safety of levetiracetam (LEV) as adjunctive therapy in children with treatment‐resistant partial‐onset seizures. Methods: Children (aged 6–12 years) with treatment‐resistant partial‐onset seizures receiving one standard antiepileptic drug (AED) were eligible. Afte...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Epilepsia (Copenhagen) Jg. 43; H. 5; S. 518 - 524
Hauptverfasser: Glauser, Tracy A., Pellock, John M., Bebin, E. Martina, Fountain, Nathan B., Ritter, Frank J., Jensen, Christof M., Shields, W. Donald
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Boston, MA, USA Blackwell Science Inc 01.05.2002
Blackwell
Schlagworte:
Age Factors
Age of Onset
Anorexia - chemically induced
Anticonvulsants - adverse effects
Anticonvulsants - blood
Anticonvulsants - therapeutic use
Anticonvulsants. Antiepileptics. Antiparkinson agents
Biological and medical sciences
Child
Children
Drug Administration Schedule
Drug Therapy, Combination
Epilepsies, Partial - blood
Epilepsies, Partial - drug therapy
Epilepsy
Female
Headache - chemically induced
Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy
Humans
Infection - chemically induced
Keppra
Levetiracetam
Male
Medical sciences
Nervous system (semeiology, syndromes)
Neurology
Neuropharmacology
Partial seizures
Pharmacology. Drug treatments
Piracetam - adverse effects
Piracetam - analogs & derivatives
Piracetam - blood
Piracetam - therapeutic use
Sleep Wake Disorders - chemically induced
Treatment Outcome
Human
Nervous system diseases
Chemotherapy
Partial
Treatment efficiency
Epilepsy
Central nervous system disease
Tolerance
Anticonvulsant
Child
Cerebral disorder
Levetiracetam
ISSN:0013-9580, 1528-1167
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose: To assess the efficacy and safety of levetiracetam (LEV) as adjunctive therapy in children with treatment‐resistant partial‐onset seizures. Methods: Children (aged 6–12 years) with treatment‐resistant partial‐onset seizures receiving one standard antiepileptic drug (AED) were eligible. After a 4‐week baseline period, children received LEV in a 6‐week titration phase (target dose, 40 mg/kg/day) followed by an 8‐week evaluation phase. Seizure frequency during the evaluation period with individualized LEV doses (20–40 mg/kg/day) were compared with the 4‐week baseline seizure frequency. Plasma concentrations of LEV and other AEDs were determined to evaluate potential drug interactions. Results: Twenty‐four subjects enrolled and received LEV; 23 entered the evaluation phase, and 22 completed the evaluation phase. Compared with their baseline seizure frequency, 12 (52%) of 23 subjects entering the evaluation phase had their seizure frequency decrease by >50%. Two subjects remained seizure free during the entire evaluation period. LEV did not significantly affect plasma concentrations of any concomitant AED during this study, and no alteration of mean clinical laboratory values was observed. The most commonly reported adverse events were headache, infection, anorexia, and somnolence. Conclusions: This open‐label study of adjunctive LEV therapy (at 20–40 mg/kg/day) suggests that LEV is effective, safe, and well tolerated in children ages 6–12 years with treatment‐resistant partial‐onset seizures. A randomized, placebo‐controlled, double‐blind trial of LEV adjunctive therapy in children with treatment‐resistant partial‐onset seizures is needed and ongoing to confirm these open‐label findings.
Bibliographie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0013-9580
1528-1167
DOI:10.1046/j.1528-1157.2002.13101.x